Metformin could inhibit the growth of prostate cancer cells in the laboratory.

Dr.Shruti Bhat, an Leader,Pharmaceutical R&D and expert in oncology product development, brings to you some highlights from current pharma and clinical research news, views and data. 

Many Oncologists Say Drugs Aimed At Disabling Proteins Are The Future Of Cancer Therapies. The New York Times reported that "drugs aimed at disabling proteins that spur cancer are, many oncologists say, the future of cancer therapies." ... 

Diabetes Drug May Help Reduce Lung Tumors.
The Los Angeles Times "Booster Shots" blog reported, "Metformin, a safe and inexpensive drug widely used to lower blood glucose in type 2 diabetics, may have a variety of other uses, researchers are finding." For example, "at an American Society of Clinical Oncology meeting on genitourinary cancers last month, Dr. Cristiano Ferrario, of McGill University in Montreal, Canada, reported that metformin could inhibit the growth of prostate cancer cells in the laboratory... 

Statins May Not Lower Risk Of Colorectal Cancer.
HealthDay reported that "statins don't lower the risk of colorectal cancer, and may even increase the chances of developing precancerous polyps," according to a study published in the journal Cancer Prevention Research...

Tailored Treatment Based On Tumor's Molecular Traits May Improve Lung Cancer Survival.
The Wall Street Journal reports that tailoring treatment based on a tumor's molecular features may improve survival in lung cancer patients, according to a study called Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) presented at the annual meeting of the American Association for Cancer Research...

FDA Okays Tarceva As Initial Maintenance Treatment For Most Common Form Of Lung Cancer.
OSI Pharmaceuticals Inc. won approval from US regulators to expand the use of its Tarceva [erlotinib] drug as an initial maintenance treatment for the most common form of lung cancer. In 2004, the drug "was approved...  

Other Gene Mutations May Inhibit Colon Cancer Drug's Effectiveness.
Amgen Inc.'s Vectibix [panitumumab], a drug for colon cancer, may be useful to even fewer patients who suffer from that illness than scientists previously found," according to a new study. "Previous research showed that Vectibix doesn't work in about 40 percent of colon cancer patients... 

More at http://www.pharm-education.com/2010/04/many-oncologists-say-drugs-aimed-at.html  

Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. 

Http://www.drshrutibhat.com
Expert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
TouTube Channel : Http://www.youtube.com/user/ShrutiBhat10

Do you have questions for the author?

---